Reportlinker Adds Shire plc: PharmaVitae Profile

Wednesday, February 17, 2010 Press Release
Email Print This Page Comment bookmark
Font : A-A+



NEW YORK, Feb. 16 Reportlinker.com announces that a new market research report is available in its catalogue:

Shire plc: PharmaVitae Profile

http://www.reportlinker.com/p0177526/Shire-plc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector

*Assess Shire's strategy for sustaining its market-leading ADHD portfolio beyond the genericization of blockbuster Adderall XR

*Analyze the impact of recent acquisitions (TKT, New River Pharmaceuticals, Jerini) on Shire's financial and sales performance over 2008-14

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 4

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Shire plc: PharmaVitae forecasts at a glance 8

Strategic insight 9

Shire's ADHD franchise growth 9

Corporate restructuring: growth via M&A 10

SWOT analysis 12

Strengths 12

Weaknesses 13

Opportunities 14

Threats 15

Table of Contents 15

Table of figures 17

Chapter 3 Quarterly news update 18

Product developments 18

Deals and alliances 19

Product deals 19

Technology deals 20

M&A activity 21

Company announcements 21

Future product milestones 22

Chapter 4 Company introduction 23

Key findings 23

Background 24

Key corporate developments 24

M&A history 25

Acquisition of Imperial Pharmaceutical Services 25

Acquisition of Pharmavene 26

Acquisition of Richwood 26

Merger with Roberts Pharmaceutical Corporation 26

Acquisition of Fuisz Technologies' EU subsidiaries 26

Acquisition of BioChem Pharma 26

Acquisition of Atlantic Pharmaceutical 26

Divestment of OTC products 26

Divestment of vaccines business 27

Acquisition of Transkaryotic Therapies 27

Acquisition of New River Pharmaceuticals 27

Divestment of non-core products 27

Acquisition of Jerini 27

Current corporate structure 28

Specialty Pharmaceuticals 28

Human Genetic Therapies 28

Chapter 5 Company sales 29

Key findings 29

Prescription pharmaceutical sales and growth rate analysis, 2002-14 30

Product analysis 32

Product analysis, 2002-08 33

Product analysis, 2008-14 36

Therapy area analysis 39

Geographic analysis 41

Launch/core/expiry analysis 44

Explanation of launch/core/expiry analysis 44

Launch analysis, 2008-14 45

Core analysis, 2008-14 47

Expiry analysis, 2008-14 48

Launch/core/expiry configuration, 2008-14 49

Molecule type analysis 50

Externalization analysis 53

Chapter 6 Company financials 55

Key findings 55

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 56

Operating costs and profit analysis 57

Operating costs and profit analysis, 2002-08 58

Operating cost ratio and profit margin analysis, 2002-08 59

Operating cost ratio and profit margin analysis, 2008-14 60

Operating costs and profit analysis, 2008-14 61

Chapter 7 Key products and competitors 62

Key findings 62

Overview 63

Central nervous system 64

Vyvanse 64

Overview 64

Sales forecast 65

Vyvanse-sustains Shire's ADHD focus beyond Adderall XR 65

Vyvanse tackles Adult ADHD market 66

Shire to gain growth in immature EU ADHD market with Vyvanse 66

Actavis' challenge to Vyvanse's US exclusivity represents a longer-term threat to sales 66

Intuniv 67

Overview 67

Sales forecast 68

Intuniv is Shire's newest ADHD offering 68

As a non-stimulant, Intuniv competes against Strattera 68

Datamonitor maintains the view that positioning as a second-line treatment option will limit uptake of Intuniv 69

More restrictive scheduling for Vyvanse raises forecasts for Intuniv 69

Daytrana 70

Overview 70

Sales forecast 71

Daytrana is the first transdermal patch formulation of methylphenidate 71

Withdrawal of Daytrana European Marketing Authorization Application (MAA) in March 2009 71

Voluntary market recall of a limited portion of Daytrana patches unlikely to threaten long-term sales 72

Endocrine, metabolic and genetic disorders 73

Elaprase 73

Overview 73

Sales forecast 74

Enzyme replacement therapy Elaprase was gained in TKT acquisition 74

Cost is also key to Elaprase's success 74

Patent protection extended in 2008 74

Replagal 75

Overview 75

Sales forecast 76

Replagal gains access to US market following Fabrazyme manufacturing concerns 76

Replagal becomes Shire's first HGT offering 76

Fabrazyme shortage grants US opportunity for Replagal 77

Velaglucerase alfa 78

Overview 78

Sales forecast 79

Limited availability of velaglucerase alfa until 2010 79

Velaglucerase alfa to compete with Genzyme's Cerezyme 79

Shire's clinical data was solid, but is there an unmet need? 80

Gastroenterology 81

Lialda / Mezavant 81

Overview 81

Sales forecast 82

Shire to roll-out Lialda across the rest of the EU 82

Lialda and Pentasa can co-exist in the US market 82

Takeda/TAP co-promotion from 2008 83

Pricing may prove a resistor to Lialda's sales growth 83

Pentasa 84

Overview 84

Sales forecast 85

Bullets Shire license Pentasa from Ferring for the US market 85

US patent expiry in 2008 unlikely to impact sales 85

Pentasa and Lialda co-exist without signs of cannibalization 86

Genitourinary 87

Fosrenol 87

Overview 87

Sales forecast 88

Fosrenol licensed from AnorMED 88

Abbott terminates co-promotion agreement for the US market 88

US market flattening out, EU and RoW to show strong growth 88

Generic threat lingers on... 89

Chapter 8 Appendix 90

R&D pipeline 90

References 91

Abbreviations 91

Exchange rates 92

About Datamonitor 93

About Datamonitor Healthcare 93

Datamonitor consulting 93

Disclaimer 94

Disclaimer 95

List of Tables

Table 1: Shire - PharmaVitae forecasts at a glance 8

Table 2: Shire key product developments, 2009 18

Table 3: Shire product deals and alliances, 2009 19

Table 4: Shire technology deals and alliances, 2009 20

Table 5: Shire M&A activity, 2009 21

Table 6: Shire company announcements, 2009 21

Table 7: Shire future product milestones, 2009-11 22

Table 8: Shire product portfolio overview ($m), 2002-08 33

Table 9: Shire product portfolio overview ($m), 2008-14 36

Table 10: Shire prescription pharmaceutical sales by therapy area ($m), 2008-14 40

Table 11: Shire prescription pharmaceutical sales by geographic region ($m), 2008-14 42

Table 12: Shire launch portfolio overview ($m), 2008-14 45

Table 13: Shire core portfolio overview ($m), 2008-14 47

Table 14: Shire expiry portfolio overview ($m), 2008-14 48

Table 15: Shire prescription pharmaceutical sales by molecule type ($m), 2008-14 51

Table 16: Shire prescription pharmaceutical sales by source ($m), 2008-14 54

Table 17: Total Shire sales by business unit ($m), 2002-08 56

Table 18: Shire operating revenue/cost analysis ($m), 2002-08 58

Table 19: Shire operating cost ratio analysis (% of total revenues), 2002-08 59

Table 20: Shire operating cost ratio analysis (% of total revenues), 2008-14 60

Table 21: Shire operating revenue/cost analysis ($m), 2008-14 61

Table 22: Key products overview 63

Table 23: Vyvanse: overview 64

Table 24: Vyvanse: sales forecast ($m), 2008-14 65

Table 25: Intuniv: overview 67

Table 26: Intuniv: sales forecast ($m), 2008-14 68

Table 27: Daytrana: overview 70

Table 28: Daytrana: sales forecast ($m), 2008-14 71

Table 29: Elaprase: overview 73

Table 30: Elaprase: sales forecast ($m), 2008-14 74

Table 31: Replagal: overview 75

Table 32: Replagal: sales forecast ($m), 2008-14 76

Table 33: Velaglucerase alfa: overview 78

Table 34: Velaglucerase alfa: sales forecast ($m), 2008-14 79

Table 35: Lialda / Mezavant: overview 81

Table 36: Lialda / Mezavant: sales forecast ($m), 2008-14 82

Table 37: Pentasa: overview 84

Table 38: Pentasa: sales forecast ($m), 2008-14 85

Table 39: Fosrenol: overview 87

Table 40: Fosrenol: sales forecast ($m), 2008-14 88

Table 41: Shire's R&D pipeline (Phase I-registration) 90

Table 42: Exchange rates, 2009 92

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Shire prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Shire's financial performance ($m), 2002-14 7

Figure 4: Shire ADHD franchise - switching strategy, 2001-14 9

Figure 5: Shire revenue by source of product, $m, 2002-14 10

Figure 6: Shire SWOT analysis 12

Figure 7: Shire M&A/divestment history 25

Figure 8: Current corporate structure 28

Figure 9: Shire prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 30

Figure 10: Key product sales ($m), 2002-14 32

Figure 11: Shire key sales growth drivers and resistors ($m), 2002-08 34

Figure 12: Shire key sales growth drivers and resistors ($m), 2008-14 37

Figure 13: Shire prescription pharmaceutical sales by therapy area ($m), 2002-14 39

Figure 14: Shire prescription pharmaceutical sales by geographic region ($m), 2002-14 41

Figure 15: Shire launch/core/expiry configuration ($m), 2008-14 49

Figure 16: Shire prescription pharmaceutical sales by molecule type ($m), 2002-14 50

Figure 17: Shire prescription pharmaceutical sales by source ($m), 2002-14 53

Figure 18: Shire operating revenue/cost analysis ($m), 2002-14 57

To order this report:

Pharmaceutical Industry: Shire plc: PharmaVitae Profile

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: [email protected] US: (805)-652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook